• Twist Bioscience Corp TWST.OQ reported a quarterly adjusted loss of 53 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -75 cents. The mean expectation of twelve analysts for the quarter was for a loss of 63 cents per share. Wall Street expected results to range from -76 cents to -51 cents per share.

• Revenue rose 24.1% to $88.71 million from a year ago; analysts expected $86.97 million.

• Twist Bioscience Corp's reported EPS for the quarter was a loss of 53 cents​.

• The company reported a quarterly loss of $31.59 million.

• Twist Bioscience Corp shares had risen by 12.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Twist Bioscience Corp is $54.00

This summary was machine generated from LSEG data February 3 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)